Ischemic heart disease in women

Southern Medical Journal

Volumn 106, Issue 7, 2013, Pages 427-433

  Ashley, Kellan E ^a,b   Geraci, Stephen A ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b East Tennessee State University   (United States)

Author keywords

Ischemic heart disease; Microvascular dysfunction; Risk stratification; Treatment; Women

Indexed keywords

CARDIAC IMAGING; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MYOCARDIAL PERFUSION IMAGING; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STRESS ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CORONARY DISEASE; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 84880312276     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31829b9eab     Document Type: Review

References (98)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012;125:e2-e220.
2. Mosca L, Mochari-Greenberger H, Dolor RJ, et al. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Cardiovascular quality and outcomes. Circ Cardiovasc Qual Outcomes 2010;3:120-127.
3. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
4. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBISponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: Gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006;47:S21-S29.
5. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBISponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47: S4-S20.
6. Shaw LJ, Shaw RE, Merz CN, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and inhospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008;117:1787-1801.
7. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: Evolving knowledge. J Am Coll Cardiol 2009;54:1561-1575.
8. Daly C, Clemens F, Lopez Sendon JL, et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006; 113:490-498.
9. Shaw LJ, Merz CN, Pepine CJ, et al. The economic burden of angina in women with suspected ischemic heart disease: Results from the National Institutes of HealthYNational Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Circulation 2006;114:894-904.
10. Gulati M, Shaw LJ, Bairey Merz CN. Myocardial ischemia in women: Lessons from the NHLBI WISE study. Clin Cardiol 2012;35:141-148.
11. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
12. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
14. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and metaanalysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-414.
15. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: A meta-analysis. Arch Intern Med 2002;162:1737-1745.
16. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 2006;296:79-86.
17. Spencer EA, Pirie KL, Stevens RJ, et al. Diabetes and modifiable risk factors for cardiovascular disease: The prospective Million Women Study. Eur J Epidemiol 2008;23:793-799.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
19. Lakoski SG, Greenland P,Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: The multi-ethnic study of atherosclerosis (MESA). Arch Intern Med 2007;167:2437-2442.
20. Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006;184:201-206.
21. Pasternak RC, Abrams J, Greenland P, et al. 34th Bethesda Conference: Task force #1VIdentification of coronary heart disease risk: Is there a detection gap? J Am Coll Cardiol 2003;41:1863-1874.
22. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107: 391-397.
23. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-333.
24. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007;297:611-619.
25. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-2116.
26. Bairey Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003;41:413-419.
27. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of HealthYNational Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276-1284.
28. Bellamy L, Casas JP, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. BMJ 2007;335:974.
29. Ratner RE. Prevention of type 2 diabetes in women with previous gestational diabetes. Diabetes Care 2007;30:S242-S245.
30. Jones LW, HaykowskyMJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-1441.
31. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
32. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
33. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 2011; 305:1305-1314.
34. Shufelt CL, Johnson BD, Berga SL, et al. Timing of hormone therapy, type of menopause, and coronary disease in women: Data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause 2011;18:943-950.
35. von Mering GO, Arant CB, Wessel TR, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: Results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:722-725.
36. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA 2002;287:1153-1159.
37. Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998;97:2110-2116.
38. Reynolds HR, Srichai MB, Iqbal SN, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation 2011;124:1414-1425.
39. Sun H, Mohri M, Shimokawa H, et al. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol 2002;39:847-851.
40. Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study. Am Heart J 2001;141:735-741.
41. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med 1996;334:1311-1315.
42. Hemingway H, Langenberg C, Damant J, et al. Prevalence of angina in women versus men: A systematic review and meta-analysis of international variations across 31 countries. Circulation 2008;117:1526-1536.
43. Canto JG, Goldberg RJ, Hand MM, et al. Symptom presentation of women with acute coronary syndromes: Myth vs reality. Arch Intern Med 2007;167:2405-2413.
44. Sharaf BL, Pepine CJ, Kerensky RA, et al. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). Am J Cardiol 2001;87:937-941.
45. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: A report from theWomen's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009;169:843-850.
46. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: Large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005;45:832-837.
47. Humphries KH, Pu A, Gao M, et al. Angina with "normal" coronary arteries: Sex differences in outcomes. Am Heart J 2008;155:375-381.
48. Reynolds HR, Farkouh ME, Lincoff AM, et al. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med 2007;167:2054-2060.
49. Hemingway H, McCallum A, Shipley M, et al. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 2006;295:1404-1411.
50. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999;341:217-225.
51. Kohli P, Gulati M. Exercise stress testing in women: Going back to the basics. Circulation 2010;122:2570-2580.
52. Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999;83:660-666.
53. Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998;32:1657-1664.
54. Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation 1998;98:1622-1630.
55. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med 2005;353:468-475.
56. Kavanagh T, Mertens DJ, Hamm LF, et al. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J Am Coll Cardiol 2003;42:2139-2143.
57. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44-e164.
58. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation 2005;111:682-696.
59. Marwick TH, Shaw LJ, Lauer MS, et al. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group. Am J Med 1999;106:172-178.
60. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiology 2004;11:171-185.
61. Pianou N, Georgakopoulos A, Anagnostopoulos CD. Positron emission tomography for risk assessment of women investigated for coronary artery disease. Cardiology 2011;118:164-167.
62. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002;346:1948-1953.
63. Vermeltfoort IA, Bondarenko O, Raijmakers PG, et al. Is subendocardial ischaemia present in patients with chest pain and normal coronary angiograms? A cardiovascular MR study. Eur Heart J 2007;28:1554-1558.
64. Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:2993-2999.
65. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation 2005;111:363-368.
66. Roman MJ, Naqvi TZ, Gardin JM, et al. American society of echocardiography report. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: A report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vasc Med 2006;11:201-211.
67. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
68. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003;41:1761-1768.
69. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002;40:505-510.
70. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356: 1503-1516.
71. Novack V, Cutlip DE, Jotkowitz A, et al. Reduction in sex-based mortality difference with implementation of new cardiology guidelines. Am J Med 2008;121:597-60.
72. Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994;74:531-537.
73. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in womenV2011 update: A guideline from the American Heart Association. Circulation 2011;123: 1243-1262.
74. Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 2006;114:1380-1387.
75. Jneid H, Fonarow GC, Cannon CP, et al. Sex differences in medical care and early death after acute myocardial infarction. Circulation 2008; 118:2803-2810.
76. Healy B. The Yentl syndrome. N Engl J Med 1991;325:274-276.
77. Roeters van Lennep JE, Zwinderman AH, Roeters van Lennep HW, et al. Gender differences in diagnosis and treatment of coronary artery disease from 1981 to 1997. No evidence for the Yentl syndrome. Eur Heart J 2000;21:911-918.
78. O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: A metaanalysis. JAMA 2008;300:71-80.
79. Lansky AJ. Outcomes of percutaneous and surgical revascularization in women. Prog Cardiovasc Dis 2004;46:305-319.
80. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-1488.
81. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000;36:381-386.
82. Abbott JD, Vlachos HA, Selzer F, et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007;99:626-631.
83. Farouque HM, Tremmel JA, Raissi Shabari F, et al. Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J Am Coll Cardiol 2005;45:363-368.
84. Weintraub WS,Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men. J Am Coll Cardiol 1994;24:81-90.
85. Al-Fiadh AH, Andrianopoulos N, Farouque O, et al. Contemporary outcomes in women undergoing percutaneous coronary intervention for acute coronary syndromes. Int J Cardiol 2011;151:195-199.
86. Kim C, Redberg RF, Pavlic T, et al. A systematic review of gender differences in mortality after coronary artery bypass graft surgery and percutaneous coronary interventions. Clin Cardiol 2007;30:491-495.
87. Duvernoy CS, Smith DE, Manohar P, et al. Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. Am Heart J 2010;159:677-683.
88. BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515.
89. Bangalore S, Fonarow GC, Peterson ED, et al. Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. Am J Med 2012;125:1000-1009.
90. Jackson EA, Moscucci M, Smith DE, et al. The association of sex with outcomes among patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction in the contemporary era: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Am Heart J 2011;161:106-112.
91. Humphries KH, Gao M, Pu A, et al. Significant improvement in short-term mortality in women undergoing coronary artery bypass surgery (1991 to 2004). J Am Coll Cardiol 2007;49:1552-1558.
92. Lanza GA, Colonna G, Pasceri V, et al. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999;84:854-856.
93. Sutsch G, Oechslin E, Mayer I, et al. Effect of diltiazem on coronary flow reserve in patients with microvascular angina. Int J Cardiol 1995;52: 135-143.
94. Chen JW, Hsu NW, Wu TC, et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974-982.
95. Kayikcioglu M, Payzin S, Yavuzgil O, et al. Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J 2003;24:1999-2005.
96. Pizzi C, Manfrini O, Fontana F, et al. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X: Role of superoxide dismutase activity. Circulation 2004;109:53-58.
97. Eriksson BE, Tyni-Lenne R, Svedenhag J, et al. Physical training in syndrome X: Physical training counteracts deconditioning and pain in syndrome X. J Am Coll Cardiol 2000;36:1619-1625.
98. Mehta PK, Goykhman P, Thomson LE, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imag 2011;4:514-522.